MA40462A - Méthode de traitement de la dépression - Google Patents

Méthode de traitement de la dépression

Info

Publication number
MA40462A
MA40462A MA040462A MA40462A MA40462A MA 40462 A MA40462 A MA 40462A MA 040462 A MA040462 A MA 040462A MA 40462 A MA40462 A MA 40462A MA 40462 A MA40462 A MA 40462A
Authority
MA
Morocco
Prior art keywords
treatment
depression
snp
genotype
patient
Prior art date
Application number
MA040462A
Other languages
English (en)
Inventor
Wayne C Drevets
Qingqin S Li
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA40462A publication Critical patent/MA40462A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Otolaryngology (AREA)

Abstract

La présente invention concerne une méthode de traitement de la dépression, par exemple, de la dépression résistante au traitement dans le cadre de laquelle le schéma de traitement est ajusté en fonction du génotype du patient au niveau du polymorphisme mononucléotidique (snp) rs4306882. Cette méthode comprend, plus précisément, les étapes consistant à déterminer la présence d'un allèle g ou t au niveau du snp rs4306882 et à administrer un schéma posologique à base de kétamine ou d'eskétamine, ledit schéma
MA040462A 2014-08-13 2015-08-12 Méthode de traitement de la dépression MA40462A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462036896P 2014-08-13 2014-08-13

Publications (1)

Publication Number Publication Date
MA40462A true MA40462A (fr) 2017-06-21

Family

ID=55301311

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040462A MA40462A (fr) 2014-08-13 2015-08-12 Méthode de traitement de la dépression

Country Status (11)

Country Link
US (1) US10098854B2 (fr)
EP (1) EP3179993B1 (fr)
JP (1) JP6545788B2 (fr)
KR (1) KR20170040800A (fr)
CN (1) CN106714789A (fr)
AU (2) AU2015301782B2 (fr)
CA (1) CA2957926A1 (fr)
IL (2) IL250490A0 (fr)
MA (1) MA40462A (fr)
MX (1) MX2017001908A (fr)
WO (1) WO2016025581A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140274981A1 (en) 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
HUE056378T2 (hu) 2013-09-13 2022-02-28 Univ Chiba Nat Univ Corp R-Ketamin és sójának alkalmazása gyógyszerekként
EP3094312B1 (fr) * 2014-01-14 2019-03-13 Children's Hospital Medical Center Compositions comprenant de la kétamine pour le traitement d'un trouble du spectre de l'autisme
AU2015318123A1 (en) 2014-09-15 2017-03-30 Janssen Pharmaceutica Nv Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression
US9844551B2 (en) 2015-01-14 2017-12-19 Children's Hospital Medical Center Compositions and methods for treatment of fragile X syndrome
CN107847469A (zh) 2015-06-27 2018-03-27 美国神农制药责任有限公司 氯胺酮透皮递送系统
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
WO2019094757A1 (fr) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Agents prophylactiques pharmacologiques contre des troubles affectifs induits par le stress chez les femelles
US11622948B2 (en) 2017-11-09 2023-04-11 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
KR20240011237A (ko) * 2017-12-22 2024-01-25 얀센 파마슈티카 엔브이 우울증 치료를 위한 에스케타민
ES2907692T3 (es) 2017-12-29 2022-04-26 Celon Pharma Sa Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento
US11980595B2 (en) 2018-02-15 2024-05-14 National University Corporation Chiba University Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases
WO2019213551A1 (fr) 2018-05-04 2019-11-07 Perception Neuroscience, Inc. Méthodes de traitement de la toxicomanie
EP3628313B1 (fr) * 2018-09-28 2025-02-12 Novohale Therapeutics, LLC Composition de kétamine pour utilisation dans un procédé de traitement de la dépression par administration pulmonaire
EP3915120A1 (fr) * 2019-01-23 2021-12-01 The Regents of the University of Michigan Support de décision pharmacogénomique pour des modulateurs des récepteurs nmda, glycinergiques et ampa
JP2022524008A (ja) 2019-03-05 2022-04-27 ヤンセン ファーマシューティカルズ，インコーポレーテッド うつ病の治療のためのエスケタミン
US20210407643A1 (en) * 2020-06-25 2021-12-30 Greenway Dna Inc. Methods and systems for providing a personalized treatment regimen using cannabinoid or psychedelic compounds
EP4329759A4 (fr) 2021-04-30 2025-07-16 Mind Medicine Inc Formes cristallines de sels de lsd
JP7846211B2 (ja) 2021-08-19 2026-04-14 デフィニウム セラピューティクス ユーエス， インコーポレイテッド 治療適用のためのｄ－リゼルグ酸ジエチルアミドの即時放出製剤

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH535201A (de) 1969-12-19 1973-03-31 Bristol Myers Co Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
JPS632932A (ja) 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
DE4312016A1 (de) 1993-04-13 1994-10-20 Goedecke Ag Stabile Ketamin-Lösungen
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
DE19619665C2 (de) 1996-05-15 2001-03-08 Goedecke Ag Racemattrennung von Ketamin
RU2224523C2 (ru) 1998-07-24 2004-02-27 Сео Хонг Ю Водный раствор, содержащий желчную кислоту, и способ его получения
US6176242B1 (en) 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
EP1103256A1 (fr) 1999-11-26 2001-05-30 Claudius Dr. med. Böck Utilisation de la kétamine pour le traitement de la dysfonction immunitaire neuroendocrine et du psyhosyndrome algogénique
CA2529857A1 (fr) 2002-07-30 2004-02-05 Peter Migaly Combinaison de therapie pour la depression, la prevention du suicide et divers troubles medicaux et psychiatriques
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20060276550A1 (en) 2005-06-03 2006-12-07 Dileep Bhagwat Topical compositions of ketamine and butamben and methods of their use
AU2007229866A1 (en) 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Intranasal administration of ketamine to treat depression
US20090306137A1 (en) 2006-05-22 2009-12-10 Wolfgang Curt D Treatment for depressive disorders
DE102007009888A1 (de) * 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
WO2009131794A1 (fr) 2008-03-27 2009-10-29 University Of Kentucky Research Foundation Combinaisons de co-médicament opioïdekétamine et norkétamine dans la gestion de la douleur
US20110038807A1 (en) 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
US20120225949A1 (en) 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
EP2992877A1 (fr) 2010-06-15 2016-03-09 Grünenthal GmbH Combinaison pharmaceutique pour le traitement de la douleur
RU2622082C2 (ru) 2011-11-14 2017-06-09 Нестек С.А. Анализы и способы выбора режима лечения пациента с депрессией
WO2013138322A1 (fr) * 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Eskétamine dans le traitement de la dépression réfractaire ou résistante aux traitements
KR20150096370A (ko) 2012-08-23 2015-08-24 스튜어트 엘. 웨그 항불안제 조성물, 제형 및 사용방법
DK2983787T3 (da) 2013-04-12 2020-01-06 Icahn School Med Mount Sinai Fremgangsmåde til behandling af posttraumatisk stresssygdom
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20160338977A1 (en) 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression

Also Published As

Publication number Publication date
US10098854B2 (en) 2018-10-16
CA2957926A1 (fr) 2016-02-18
AU2020281101A1 (en) 2021-01-07
MX2017001908A (es) 2017-08-08
IL279627A (en) 2021-03-01
AU2015301782B2 (en) 2020-09-03
EP3179993A4 (fr) 2018-03-28
JP6545788B2 (ja) 2019-07-17
IL250490A0 (en) 2017-03-30
EP3179993B1 (fr) 2021-01-20
EP3179993A1 (fr) 2017-06-21
WO2016025581A1 (fr) 2016-02-18
KR20170040800A (ko) 2017-04-13
JP2017524719A (ja) 2017-08-31
AU2015301782A1 (en) 2017-03-02
CN106714789A (zh) 2017-05-24
US20160045455A1 (en) 2016-02-18

Similar Documents

Publication Publication Date Title
MA40462A (fr) Méthode de traitement de la dépression
IL279119A (en) VAL66MET genotype-specific dosage regimens (SNP rs6265) and methods for treating depression
MX2017008183A (es) Nucleosidos sustituidos, nucleotidos y analogos de estos.
MX2017008184A (es) Nucleosidos sustituidos, nucleotidos y analogos de estos.
PH12016502564A1 (en) Substituted nucleosides, nucleosides and analogs thereof
MY206629A (en) Detection processes using sites of chromosome interaction
MX2020013278A (es) Analogos de nucleotidos.
PH12016502563A1 (en) Substituted nucleosides, nucleotides and analogs thereof
PH12016500660A1 (en) Substituted nucleosides, nucleotides and analogs thereof
PH12015501423A1 (en) Substituted nucleosides, nucleotides and analogs thereof
MX2016017382A (es) Metodos para preparar analogos de nucleotido sustituidos.
PH12014502094A1 (en) Substituted nucleosides, nucleotides and analogs thereof
PH12016500486A1 (en) Aza-pyridone compounds and uses thereof
EP3212658A4 (fr) Analogues de 2',2'-dihalo-nucléosides utilisables en vue du traitement d'infections par des virus de la famille des flaviviridae et du cancer
MX370085B (es) Compuestos de piridazinona y usos de los mismos.
BR112017006680A2 (pt) variantes de vírus influenza a
MX2017008280A (es) Proceso para elaborar cenicriviroc y analogos relacionados.
MX2016017124A (es) Proceso para la preparacion de acidos 3-hidroxipicolinicos.
WO2015109318A3 (fr) Méthodes thérapeutiques
MX2017012027A (es) Desaminacion de nucleosidos organofosforados.
MX2017000318A (es) Derivados del acido abscisico sustituido en 3'.
TW201612142A (en) Process for preparing 3-chloro-2-vinylphenol
MX385963B (es) Procedimiento para la preparacion de 4-amino-1-( (1s, 4r, 5s) -2-fluoro-4,5-dihidroxi-3-hidroximetil-ciclopent-2-enil)-1h-pirimidin-2-ona.
DK3148588T3 (en) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease
WO2016025494A3 (fr) Méthodes de suivi d'adhésion à une thérapie par la quétiapine